Mexico and GLP1s

Most of the time we focus on developments within the US that relate to GLP1 receptor agonists, but it's important to note that rules (prices, regulation, etc) are completely different for different countries.

As you might expect, use of GLP1s is soaring in other countries as well, with projections for Mexico looking to be quite dramatic:

Mexico GLP-1 Receptor Agonist Market Size & Outlook, 2030

The glp-1 receptor agonist market in Mexico is expected to reach a projected revenue of US$ 788.5 million by 2030. A compound annual growth rate of 18.7% is expected of Mexico glp-1 receptor agonist market from 2025 to 2030.

Again, the graph below is mostly projection (we're not in 2026), but it's illustrative and not completely unbelievable (though there is a wobble in 2020/2021, likely due to the Coronavirus epidemic):

Whether this projection comes to pass or not, companies are starting today to prepare for such a possible future, and the news of increasing sales for Wegovy, Ozempic, Mounjaro, and other GLP1s in other countries is a good reason to do so.

Want to read more about the GLP1 ecosystem in Mexico, and generics that might be spawned there? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack: